Lori E. Dodd
#140,794
Most Influential Person Now
American mathematical statistician
Lori E. Dodd's AcademicInfluence.com Rankings
Lori E. Doddmathematics Degrees
Mathematics
#8099
World Rank
#11000
Historical Rank
Statistics
#1134
World Rank
#1239
Historical Rank
Measure Theory
#3524
World Rank
#4158
Historical Rank
Download Badge
Mathematics
Lori E. Dodd's Degrees
- PhD Statistics Stanford University
- Masters Statistics Stanford University
- Bachelors Mathematics University of California, Berkeley
Similar Degrees You Can Earn
Why Is Lori E. Dodd Influential?
(Suggest an Edit or Addition)According to Wikipedia, Lori Elizabeth Dodd is an American mathematical statistician specializing in clinical trials methodology, statistical analysis of genomic data, design of clinical trials using biomarkers and imaging modalities, and statistical methods for analyzing biomarkers. She is a statistician in the biostatistics research branch at the National Institute of Allergy and Infectious Diseases.
Lori E. Dodd's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (2009) (17488)
- Remdesivir for the Treatment of Covid-19 — Final Report (2020) (4464)
- The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. (2011) (1735)
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (2020) (1138)
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. (2019) (1061)
- A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. (2016) (369)
- Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure (2016) (180)
- Frequency, Severity, and Prediction of Tuberculous Meningitis Immune Reconstitution Inflammatory Syndrome (2012) (169)
- Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (2008) (152)
- Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply. (2020) (150)
- Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel. (2012) (120)
- Validation of novel imaging methodologies for use as cancer clinical trial end-points. (2009) (117)
- Recommendations for the assessment of progression in randomised cancer treatment trials. (2009) (111)
- PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis (2014) (110)
- Lessons learned from independent central review. (2009) (101)
- PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis (2014) (101)
- Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis (2015) (92)
- Semiparametric Regression for the Area Under the Receiver Operating Characteristic Curve (2003) (81)
- Assessment methodologies and statistical issues for computer-aided diagnosis of lung nodules in computed tomography: contemporary research topics relevant to the lung image database consortium. (2004) (81)
- Genes Involved in DNA Repair and Nitrosamine Metabolism and Those Located on Chromosome 14q32 Are Dysregulated in Nasopharyngeal Carcinoma (2006) (80)
- Evaluation of perceived threat differences posed by filovirus variants. (2011) (75)
- Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial (2021) (75)
- Efficacy and Safety of Metronidazole for Pulmonary Multidrug-Resistant Tuberculosis (2013) (63)
- Evaluating imaging and computer-aided detection and diagnosis devices at the FDA. (2012) (62)
- Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012 (2014) (56)
- Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. (2012) (54)
- A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets (2015) (48)
- On Estimating Diagnostic Accuracy From Studies With Multiple Raters and Partial Gold Standard Evaluation (2008) (45)
- No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. (2014) (44)
- Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. (2016) (43)
- Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial (2022) (42)
- Endpoints for randomized controlled clinical trials for COVID-19 treatments (2020) (42)
- Blinded independent central review of the progression-free survival endpoint. (2010) (40)
- Platform Trials — Beware the Noncomparable Control Group (2021) (37)
- Cytokine and Chemokine Profiles following Vaccination with Human Papillomavirus Type 16 L1 Virus-Like Particles (2007) (37)
- Correcting log ratios for signal saturation in cDNA microarrays (2004) (37)
- Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB (2016) (36)
- Increased Metabolic Activity on 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Human Immunodeficiency Virus–Associated Immune Reconstitution Inflammatory Syndrome (2018) (35)
- Plasma metalloproteinase levels are dysregulated in signal transducer and activator of transcription 3 mutated hyper-IgE syndrome. (2011) (31)
- Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials (2013) (30)
- Regression Analysis for the Partial Area Under the ROC Curve (2006) (29)
- Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. (2011) (28)
- An Audit Strategy for Progression‐Free Survival (2011) (27)
- FDG-PET lymphoma demonstration project invitational workshop. (2007) (27)
- A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups (2019) (25)
- Statistical considerations for a trial of Ebola virus disease therapeutics (2016) (25)
- Measurement error in the timing of events: effect on survival analyses in randomized clinical trials (2010) (23)
- Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure (2011) (18)
- A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma (2015) (18)
- Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial (2017) (18)
- Re‐randomization tests in clinical trials (2019) (17)
- Gene Expression Patterns Induced by HPV-16 L1 Virus-Like Particles in Leukocytes from Vaccine Recipients1 (2009) (16)
- Using audit information to adjust parameter estimates for data errors in clinical trials (2012) (15)
- Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis (2021) (15)
- Diagnosis of paediatric tuberculosis: the culture conundrum. (2013) (15)
- Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials (2013) (14)
- Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone (2011) (13)
- Elevations in D-dimer and C-reactive protein are associated with the development of osteonecrosis of the hip in HIV-infected adults (2013) (13)
- Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis. (2017) (11)
- Brain 18F-FDG PET of SIV-infected macaques after treatment interruption or initiation (2018) (11)
- Analysis of progression-free survival data using a discrete time survival model that incorporates measurements with and without diagnostic error (2010) (10)
- Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for Helicobacter pylori and Mycobacterium tuberculosis in Bamako, Mali (2016) (9)
- A modest proposal for dropping poor arms in clinical trials (2014) (9)
- Pulmonary Manifestations of the Autoimmune Lymphoproliferative Syndrome. A Retrospective Study of a Unique Patient Cohort. (2016) (8)
- Isoniazid preventive therapy in HIV infection (2011) (8)
- Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data (2021) (8)
- Controlling the family-wise error rate in multi-arm, multi-stage trials (2017) (7)
- The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. (2018) (6)
- Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization (2021) (5)
- Clinical trials during the Ebola crisis (2016) (5)
- ROC Curves for Continuous Data by KRZANOWSKI, W. J. and HAND, D. J. (2010) (5)
- Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] (2021) (4)
- The Bootstrap Variance of the Square of a Sample Mean (2007) (3)
- An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology (2013) (3)
- Immune correlates analysis using vaccinees from test negative designs. (2020) (2)
- Lack of generalizability of sensitivity and specificity with treatment effects (2008) (2)
- Innovative trial designs to improving tuberculosis drug development. (2013) (2)
- 121. Improving Predictive Value of Phase 2a TB Drug Development Models Through PET/CT Imaging (NexGen EBA) (2018) (2)
- University of Pennsylvania 8th annual conference on statistical issues in clinical trials: Pragmatic clinical trials (morning panel) (2016) (2)
- Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials (2023) (1)
- Gene expression patterns induced by HPV‐16 L1 VLP in leukocytes from vaccine recipients (2008) (1)
- Inherent difficulties in nonparametric estimation of the cumulative distribution function using observations measured with error: Application to high-dimensional microarray data (2014) (1)
- Data and Safety Monitoring Board Monitoring of Clinical Trials for Early Efficacy (2022) (0)
- Matched Longitudinal Analysis of Biomarkers Associated with Survival (2014) (0)
- Defining the immune correlates of pathogenicity of Simian Hemorrhagic Fever virus in Rhesus macaques (P6314) (2013) (0)
- Utility of Fluorodeoxyglucose Positron Emission Tomography(FDG-PET) and Biomarkers, Serum Vitamin B12 and HDL for Assessing Lymphoproliferation in Children and Adults with Autoimmune Lymphoproliferative Syndrome Due to FAS Mutations (ALPS-FAS) (2016) (0)
- Monitoring Immune Activation with Whole-Body Fluorodeoxyglucose–Positron-Emission Tomography in Simian Immunodeficiency Virus–Infected Rhesus Macaques (2021) (0)
- 789. Viral and Immunologic biomarkers of COVID-19 improve risk stratification and identify patients most likely to benefit from therapy with remdesivir (2022) (0)
- Baricitinib treatment of COVID-19 is associated with a reduction of secondary infections (2023) (0)
- PSA velocity and prostate cancer. (2004) (0)
- Commentary on Tinè et al. (2017) (0)
- On the importance and challenges of global access to proven life-saving treatments for Ebolavirus. (2023) (0)
- 931A Prospective, Controlled Study of Multidrug-Resistant Organism Colonization among Healthcare Personnel (2014) (0)
- TuberculosisMultidrug-Resistant Efficacy and Safety of Metronidazole for (2013) (0)
- measurements with and without diagnostic error Analysis of progression-free survival data using a discrete time survival model that incorporates (2010) (0)
- A sterilizing tuberculosis treatment regimen is associated with faster clearance of 3 bacteria in cavitary lesions in marmosets . 4 5 Running title : Sterilizing TB treatment in marmosets 6 7 (2015) (0)
- Effects of Remdesivir in Hospitalized Patients with COVID-19: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials (2022) (0)
- Reply to D.L. Raunig (2009) (0)
- How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19 (2021) (0)
- Panduan Penulisan Naskah Ilmiah (2017) (0)
- Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE) (2022) (0)
- Predicting TB treatment outcomes using baseline risk and treatment response markers: developing the PredictTB early treatment completion criteria (2020) (0)
- Tuberculosis Pulmonary Multidrug-Resistant Efficacy and Safety of Metronidazole for (2013) (0)
This paper list is powered by the following services:
Other Resources About Lori E. Dodd
What Schools Are Affiliated With Lori E. Dodd?
Lori E. Dodd is affiliated with the following schools:
